Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ziopharm Oncology
Biotech
Alaunos winds down sole cell therapy trial, cuts 60% of staff
Alaunos is cutting loose its sole clinical-stage asset and letting 60% of staff go less than two years after refocusing on TCR-T cell therapies.
Max Bayer
Aug 15, 2023 10:53am
Former BMS R&D chief Vessey jumping to Flagship—Chutes & Ladders
Jul 14, 2023 9:30am
Ziopharm rebrands to Alaunos to put rough year behind it
Jan 26, 2022 10:58am
Ziopharm's new CEO fires half of his workforce in first month
Sep 28, 2021 10:05am
Ziopharm hires new CEO
Aug 30, 2021 10:39am
Ziopharm's IL-12 gene therapy boosts survival in brain cancer
May 29, 2020 8:00am
